Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation

LUND, SE / ACCESS Newswire / March 17, 2026 / Spago Nanomedical AB (publ) (STO:SPAGO.ST)(FRA:7UX.F) announced today that the independent Data Monitoring Committee (DMC) recommends that the ongoing clinical phase I/IIa study Tumorad-01 with the drug …